Bayer Investor Relations

Team having a chat
Investor News
Share Price / Index
March 23, 2026
Not intended for U.S. and UK Media
Eylea™ 8 mg approved for third retinal indication in Japan
March 23, 2026
First approval for Bayer’s low-dose MRI contrast agent in Japan
March 16, 2026
Not intended for U.S. and UK Media
Finerenone meets primary endpoint in pivotal Phase III FIND-CKD study in patients with non-diabetic chronic kidney disease